



DIA 2022
GLOBAL ANNUAL MEETING

CHICAGO, IL
JUNE 19-23

Medable Innovation Theater: Modeling ROI of DCT Solution Deployment

Pamela Tenaerts
Chief Science Officer
Medable, Inc

On behalf of the Medable Team
Mary Costello
Andrew MacKinnon
Ingrid Oakley-Girvan

@PamelaTenaerts

@Medable



Medable's eNPV work



Medable took a leadership position by commissioning this work from the Tufts CSDD group and contributed with data and discussion analysis



It is a financial metric, built upon additional measures



One of the first hard metrics around DCTs



Many metrics and more data to come on DCT adoption




DIA
2022

GLOBAL
ANNUAL
MEETING

CHICAGO, IL
JUNE 19-23

Financial Return on Investment Expected Net Present Value



A common technique that integrates the key business drivers of cost, time, revenue, and risk into a summary metric for project strategy and portfolio decisions



DIA
2022

GLOBAL
ANNUAL
MEETING

CHICAGO, IL
JUNE 19-23


Impact of DCTs to eNPV



DIA
2022

GLOBAL
ANNUAL
MEETING

CHICAGO, IL
JUNE 19-23



Adapted from Clinical Trials Transformation Initiative
Considerations of net present value in policy making regarding diagnostic and therapeutic technologies Robert M. Califf, MD, Am Heart J 2008;156:879-85

Not to Scale

Takeaways

- ▶ This is real data
 - Actual protocol performance pre Covid
 - Mean contract value from Medable contracts
- ▶ This model reflects a base case based on historical data with modest 5-10% in cycle time improvements that lead to
 - 5 times ROI on phase 2 investments
 - 13 times ROI on Phase 3 investments
- ▶ The work is not done: We need to continue to refine and rerun model with more actual and more granular data



DIA
2022

GLOBAL
ANNUAL
MEETING

CHICAGO, IL
JUNE 19-23

Stay Tuned



Peer Reviewed Paper



More metrics and data



DIA
2022

GLOBAL
ANNUAL
MEETING

CHICAGO, IL
JUNE 19-23